Ken Griffin Surface Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.61 - $1.03 $33,184 - $56,032
-54,400 Reduced 94.77%
3,000 $2,000
Q4 2022

Feb 14, 2023
BUY
$0.62 - $1.21 $4,526 - $8,833
7,300 Added 14.57%
57,400 $47,000
Q3 2022

Nov 14, 2022
SELL
$1.05 - $2.1 $25,305 - $50,610
-24,100 Reduced 32.48%
50,100 $52,000

Others Institutions Holding SURF

# of Institutions
2
Shares Held
315K
Call Options Held
0
Put Options Held
0
View Full List

About Surface Oncology, Inc.

SURF Quotes by TradingView
  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email